InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at Lake Street Capital

Investment analysts at Lake Street Capital began coverage on shares of InspireMD (NYSE:NSPR) in a note issued to investors on Wednesday,Benzinga reports. The brokerage set a “buy” rating and a $5.00 price target on the stock. Lake Street Capital’s price target suggests a potential upside of 58.73% from the company’s current price.

A number of other analysts have also weighed in on the stock. Piper Sandler reissued an “overweight” rating and issued a $4.50 price target on shares of InspireMD in a report on Tuesday, September 17th. StockNews.com started coverage on shares of InspireMD in a report on Wednesday, December 4th. They issued a “sell” rating for the company.

InspireMD Stock Up 0.3 %

Shares of NSPR traded up $0.01 during mid-day trading on Wednesday, reaching $3.15. The company’s stock had a trading volume of 25,077 shares, compared to its average volume of 29,285. The business has a fifty day moving average of $2.64 and a 200 day moving average of $2.67. The company has a market cap of $82.16 million, a price-to-earnings ratio of -4.20 and a beta of 0.98. InspireMD has a 1 year low of $1.81 and a 1 year high of $3.42.

InspireMD (NYSE:NSPR) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. The business had revenue of $1.81 million for the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. During the same period in the prior year, the business posted ($0.15) earnings per share. On average, analysts predict that InspireMD will post -0.79 earnings per share for the current year.

Institutional Investors Weigh In On InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Parkman Healthcare Partners LLC bought a new stake in InspireMD, Inc. (NYSE:NSPR) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 104,081 shares of the company’s stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned about 0.42% of InspireMD as of its most recent SEC filing. 44.78% of the stock is owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.